First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006)

Infection

Volumn 35, Issue 3, 2007, Pages 134-142

  Carosi, G ^a   Quiros Roldan, E ^a   Torti, C ^a   Antinori, A ^b   Bevilacqua, M ^c   Bonadonna, R C ^d   Bonfanti, P ^c   Castagna, A ^e   Cauda, R ^f   D'Arminio Monforte, A ^g   Di Gregorio, P ^h   Di Perri, G ⁱ   Esposito, R ^j   Fatuzzo, F ^k   Gervasoni, C ^l   Giannattasio, C ^m   Guaraldi, G ^j   Lazzarin, A ^e   Lo Caputo, S ⁿ   Maggi, P ^o   Mazzotta, F ⁿ   Moroni, M ^l   Prestileo, T ^p   Ranieri, R ^q   Rizzardini, G ^c   Russo, R ^q   Galli, M ^l   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b Lazzaro Spallanzani   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e IRCCS   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h UOC Malattie Infettive PO Ferrarotto AOU Policlinico Vittorio Emanuele Catania   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k Universitaria Ferrarotto S Bambino   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m SAN GERARDO HOSPITAL   (Italy)

ⁿ SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^o POLICLINICO   (Italy)

^p Ospedale Casa del Sole   (Italy)

^q UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; EFAVIRENZ; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; METFORMIN; MEVINOLIN; NEVIRAPINE; OMEGA 3 FATTY ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SIMVASTATIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; DIABETES MELLITUS; DIET; DRUG EXPOSURE; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; QUALITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DRUG INTERACTIONS; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; ITALY; MALE; RISK FACTORS;

EID: 34250679256     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6295-5     Document Type: Article

References (34)

1. The Data Collection on Adverse Events of Anti-HIV-Drugs (DAD) Study Group: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003 (Erratum, N Engl J Med 2004; 350: 955).
2. Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V: Key questions in antiretroviral therapy: Italian consensus workshop (2005). J Antimicrob Chemother 2006; 57: 1055-1064.
3. Grinspoon S, Carr A: Cardiovascular risk and body fat abnormalities in HIV infected adults. N Engl J Med 2005; 352: 48-62.
4. Carr A, Grund B, Neuhaus J, El-Sadr W, Grandits G, Gibert C, Neaton J, Prineas R: ART and asymptomatic ischemic heart disease in HIV-infected adults: a cross-sectional analysis of patients enrolling in the SMART trial. In: Program and abstracts in the 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado. Abstract 736.
5. Vassalle C, Masini S, Bianchi F, Zucchelli GC: Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90: 565-566.
6. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA: No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006; 43: e53-e56.
7. Hemmelgarn BR, McAlister FA, Grover S, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Honos G, Burgess E, Mann K, Wilson T, Penner B, Tremblay G, Milot A, Chockalingam A, Touyz RM, Tobe SW: The 2006 canadian hypertension education program recommendations for the management of hypertension: Part I-blood pressure measurement, diagnosis and assessment of rish. Can J Cardiol 2006; 22: 573-581.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seven Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 290: 2560-2572.
9. Yusuf S, Hawken S, Ounpuu S, On behalf of the INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet 2004; 364: 937-952.
10. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Sitthi-amorn C, Sato H, Yusuf S: Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 953-962.
11. Haffner SM, Despres JP, Balkau B: Waist circumference and body mass index are both independently associated with cardiovascular disease: The International Day for the Evaluation of Abdominal Obesity (IDEA) survey. J Am Coll Cardiol 2006; 47 (4 Suppl A): 358A (Abstract 842-846).
12. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
13. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
14. Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR, Handelsman Y, Jellinger PS, Levy P, Riddle MC, Roberts VL, Siminerio LM: ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendation. Endocr Pract 2006; 12 (Suppl 1): 6-12.
15. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H: Association between insulin resistance, and hepatitis C virus chronic infection in HIV-hepatitis C virus coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 245-250.
16. Palacios R, Merchante N, Macias J, Gonzalez M, Castillo J, Ruiz J, Marquez M, Gomez-Mateos J, Pineda JA, Santos J: Incidence and risk factors for insulin resistance in treatment naïve HIV-infected patients 48 weeks after starting highly active antiretroviral therapy Antiviral Ther 2006;11:529-535.
17. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD: Modelling the 3-year risk of myocardial infarction among participants in the Data collection on adverse events of anti-HIV drugs (DAD) study. HIV Med 2003; 4: 1-10.
18. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC: Lipid profiles for anti-retroviral naive patients starting PI and NNRTI based therapy in the Swiss HIV Cohort study. Antivir Ther 2005; 10: 585 -591.
19. Sax PE, Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004; 37: 1111-1124.
20. Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Perez S, Zapata A, Gonzalez-Garcia JJ, Pena JM, Vazquez JJ, Arribas JR: Lipid disorders in antiretroviral naïve patients treated with lopinavir/ritonavir based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005; 55: 800-804.
21. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral therapy naive patients infected with HIV. Plos Med 2004; 1: e19.
22. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naïve patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
23. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C: Single dose lopinavir-ritonavir acutely inhibits insulin mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43: 658-660.
24. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB, Dobs AS: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicentre AIDS Cohort Study. AIDS 2005; 19: 1375-1383.
25. Negredo E, Bonjoch A, Clotet B: Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrobiol Chemother 2006; 58: 235-242.
26. Mulligan K, Yang Y, Koletar S, Wininger D, Parker R, Alston-Smith B, Basar M, Grinspoon S: Effects of metformin and rosiglitazone on body composition in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio: a randomized, placebo-controlled trial. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Abstract 147.
27. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized double blind, placebo-controlled trial. Lancet 2004; 363: 429-438.
28. Stein JH: Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 2005; 38: 115-123.
29. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin. Results of the AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005; 39: 307-312.
30. Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Leiter LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Herbert C, Milot A, Stone JA, Burgess E, Hemmelgarn B, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM: The 2006 canadian hypertension education program recommendations for the management of hypertension: part II-therapy. Can J Cardiol 2006; 22: 583-593.
31. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G: Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-1382.
32. Palacios R, Santos J, Garcia A, Castells E, Gonzalez M, Ruiz J, Marquez M: Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naïve patients. HIV Med 2006; 7: 10-15.
33. Thiebaur R, El-Sadr WM, Friis-Moller N, Rickenbach M, Reiss P, Monforte AD, Morfeldt L, Fontas E, Kirk O, De Wit S, Calvo G, Law MG, Dabis F, Sabin CA, Lundgren JD: Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10: 811-823 (Erratum in: Antiviral Ther 2005; 10: 969).
34. Crane HM, van Rompaey SE, Kitahata MM: Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20: 1019-1026.